Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Current Liabilities (2017 - 2025)

Puma Biotechnology's Total Current Liabilities history spans 9 years, with the latest figure at $81.3 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 15.46% year-over-year to $81.3 million; the TTM value through Dec 2025 reached $81.3 million, down 15.46%, while the annual FY2025 figure was $81.3 million, 15.46% down from the prior year.
  • Total Current Liabilities reached $81.3 million in Q4 2025 per PBYI's latest filing, down from $82.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $140.4 million in Q1 2021 to a low of $48.2 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $89.4 million, with a median of $84.7 million recorded in 2025.
  • Peak YoY movement for Total Current Liabilities: plummeted 58.79% in 2022, then soared 103.77% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $109.6 million in 2021, then dropped by 29.29% to $77.5 million in 2022, then increased by 28.26% to $99.4 million in 2023, then decreased by 3.29% to $96.1 million in 2024, then fell by 15.46% to $81.3 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Total Current Liabilities are $81.3 million (Q4 2025), $82.7 million (Q3 2025), and $79.1 million (Q2 2025).